A Phase I/IIa, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous and Intravenous Doses of PRO044 in Patients With Duchenne Muscular Dystrophy

Trial Profile

A Phase I/IIa, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous and Intravenous Doses of PRO044 in Patients With Duchenne Muscular Dystrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs BMN 044 (Primary) ; BMN 044 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Prosensa
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top